本帖最后由 老马 于 2012-1-13 21:20 编辑 . W/ b1 @! j6 S) w& u0 H6 i
4 t. }. g2 x, _9 }+ n. _0 h
爱必妥和阿瓦斯丁的比较
6 K" c9 {" ~3 t/ r# ]- l& t
$ w0 |; R5 S3 J( N
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ p. g& [- D% ~" h% {7 @
) e3 m' H) Y8 q- _" B$ k
1 h$ n' _3 A- m- F5 i) X7 ?
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/2 a. H! H/ c1 ~* H5 \0 H
==================================================) ^5 B9 I& R/ M1 Y9 K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# h0 [1 e$ q5 s; Y) C2 E* `, DPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; i" O! [7 p, g# vResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.: F: e6 P" j5 a( b. j
|